← Eichor
Study identifier: NCT05211986 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

Condition: Muscle Atrophy  ·  Sponsor: Immunis, Inc.

PhasePhase 1/Phase 2
Planned participants28
Who can joinAll sexes, 50 Years to 75 Years
Healthy volunteersYes

About this study

An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis

This description comes directly from the study's public registry record.

Talk to the study team

Joelle Hafen, BS  ·  9492662501  ·  Joelle@immunisbiomedical.com

Erin Curry, PA  ·  9492662501  ·  Erin@immunisbiomedical.com

Always discuss trial participation with your own doctor first.

Locations (2)

Orthopaedic Specialty InstituteIrvine, California, United StatesRecruiting
University of California, Irvine - Alpha Stem Cell ClinicOrange, California, United StatesActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05211986